FIGURES AND TABLES
FROM:
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, V Cabaret, V Fermeaux, P Bertheau, J Garnier, J-F Jeannin and B Coudert
BACK TO ARTICLE
Figure 1.
Immunohistochemical staining with NK1. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with NK1. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.
Full figure and legend (370K)
Figure 2.
Immunohistochemical staining with CD56. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B) both stained with CD56. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.
Full figure and legend (393K)
Figure 3.
Immunohistochemical staining with Granzyme B. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with Granzyme B. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.
Full figure and legend (374K)
Figure 4.
Immunohistochemical staining with TiA1. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with TiA1. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.
Full figure and legend (334K)
